Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Emanuel F. Petricoin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9146-5572; OpenAlex author ID A5023762376. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
115
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 25

  1. Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
  2. Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. Co-author DOI 10.1200/po-24-00684↗
  3. Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance Co-author DOI 10.64898/2025.12.01.691471↗
  4. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/ajcp/aqae038↗
  5. Quantitative proteomic analysis of HER2 protein expression in PDAC tumors. Co-author DOI 10.1186/s12014-024-09476-7↗
  6. Keratin 17 modulates the immune topography of pancreatic cancer. Co-author DOI 10.1186/s12967-024-05252-1↗
  7. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy. Co-author DOI 10.1200/po.22.00648↗
  8. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Co-author DOI 10.1158/0008-5472.can-21-1443↗
  9. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗
  10. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Co-author DOI 10.1016/j.jbc.2021.101335↗
  11. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  12. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. Co-author DOI 10.1200/po.20.00494↗
  13. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Last author DOI 10.1016/s1470-2045(20)30074-7↗
  14. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  15. Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-1006↗
  16. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  17. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. Last author DOI 10.1200/po.19.00115↗
  18. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Last author DOI 10.1158/1078-0432.ccr-18-0531↗
  19. Molecular Profiling of Pancreatic Cancer Patients-Response. First author DOI 10.1158/1078-0432.ccr-18-2645↗
  20. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Co-author DOI 10.1016/j.ccell.2015.11.011↗
  21. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer ce… Co-author DOI 10.1038/onc.2015.325↗
  22. Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. Last author DOI 10.1007/s00216-013-6880-7↗
  23. MS analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. Last author DOI 10.1002/elps.201200017↗
  24. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. Co-author DOI 10.1021/pr100213b↗
  25. Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. Last author DOI 10.1021/pr101179t↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Jon Pishvaian · 8 shared papers, 2018–2025 · strength 1.02
  2. Andrew Eugene Hendifar · 7 shared papers, 2018–2025 · strength 0.93
  3. Adrienne D. Cox · 8 shared papers, 2016–2025 · strength 0.79
  4. Channing J. Der · 8 shared papers, 2016–2025 · strength 0.79
  5. Lynn McCormick Matrisian · 6 shared papers, 2018–2024 · strength 0.72
  6. Kirsten L. Bryant · 7 shared papers, 2016–2025 · strength 0.68
  7. Mariaelena Pierobon · 7 shared papers, 2016–2022 · strength 0.59
  8. Clint A. Stalnecker · 5 shared papers, 2019–2025 · strength 0.56
  9. Bjoern Papke · 6 shared papers, 2019–2022 · strength 0.54
  10. J. Nathaniel Diehl · 5 shared papers, 2019–2021 · strength 0.41
  11. Jennifer E. Klomp · 5 shared papers, 2019–2021 · strength 0.41
  12. Jonathan Robert Brody · 5 shared papers, 2016–2021 · strength 0.37
  13. Wei Jiang · 3 shared papers, 2016–2024 · strength 0.37
  14. Lucia Roa‐Peña · 2 shared papers, 2024 · strength 0.33
  15. Brent K. Larson · 2 shared papers, 2024 · strength 0.33
  16. Lyanne Delgado Coka · 2 shared papers, 2024 · strength 0.33
  17. Luisa F. Escobar‐Hoyos · 2 shared papers, 2024 · strength 0.33
  18. Kenneth Reed Shroyer · 2 shared papers, 2024 · strength 0.33
  19. Andrew M. Waters · 4 shared papers, 2019–2021 · strength 0.31
  20. Lee M. Graves · 2 shared papers, 2021–2025 · strength 0.31
  21. Jonathan M. DeLiberty · 3 shared papers, 2020–2022 · strength 0.30
  22. Craig M. Goodwin · 3 shared papers, 2020–2022 · strength 0.30
  23. Kristina Drizyte‐Miller · 2 shared papers, 2021–2025 · strength 0.30
  24. Charles J. Yeo · 3 shared papers, 2016–2023 · strength 0.29
  25. Timothy Lewis Cannon · 2 shared papers, 2021–2024 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.